Teva Pharmaceutical Industries Balance Sheet
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Teva Pharmaceutical Industries financial position
At the end of fiscal 2025, Teva Pharmaceutical Industries reported total assets of $40.75 billion, up 3.6% from a year earlier against total liabilities of $32.83 billion. Shareholders' equity stood at $7.91 billion, or 19.4% of assets. The company held $3.56 billion in cash and equivalents against $1.82 billion of debt, a net cash position of $1.74 billion.
The current ratio (current assets divided by current liabilities) was 1.04, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.23.
Summary generated from market data by MetaCap's automated system. Methodology
Teva Pharmaceutical Industries balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 3.56B | 3.30B | 3.23B | 2.80B | 2.17B | 2.18B | 1.98B | 1.78B | 963.00M | 988.00M |
| Receivables | 3.71B | 3.06B | 3.41B | 3.70B | 4.53B | 4.58B | 5.68B | 5.82B | 7.13B | 7.52B |
| Inventory | 3.18B | 3.01B | 4.02B | 3.83B | 3.82B | 4.40B | 4.42B | 4.73B | 4.92B | 4.95B |
| Total Current Assets | 13.95B | 12.55B | 12.48B | 12.05B | 12.57B | 13.01B | 13.46B | 13.79B | 15.38B | 17.23B |
| Property, Plant & Equipment | 4.08B | 4.58B | 5.75B | 5.74B | 5.98B | 6.30B | 6.44B | 6.87B | 7.67B | 8.07B |
| Goodwill | 16.00B | 16.00B | 17.18B | 17.18B | 17.63B | 20.62B | 24.85B | 24.92B | 28.41B | 44.41B |
| Intangible Assets | 3.78B | 4.42B | 5.39B | 6.27B | 7.47B | 8.92B | 11.23B | 14.01B | 17.64B | 21.49B |
| Total Assets | 40.75B | 39.33B | 43.48B | 44.01B | 47.67B | 50.64B | 57.47B | 60.68B | 70.61B | 93.06B |
| Accounts Payable | 225.00M | 158.00M | 108.00M | 1.89B | 1.69B | 1.76B | 1.72B | 1.85B | 2.07B | 2.16B |
| Short-Term Debt | 1.82B | 1.78B | 1.67B | 2.11B | 1.43B | 3.19B | 2.35B | 2.22B | 3.65B | 3.28B |
| Total Current Liabilities | 13.46B | 12.80B | 12.25B | 11.47B | 11.03B | 13.16B | 13.67B | 14.32B | 17.92B | 18.49B |
| Long-Term Debt | — | — | — | — | — | — | — | — | 28.83B | 32.52B |
| Total Liabilities | 32.83B | 33.61B | 35.35B | 35.41B | 36.42B | 39.58B | 42.41B | 44.89B | 51.87B | 58.06B |
| Shareholders' Equity | 7.91B | 5.37B | 7.51B | 7.80B | 10.28B | 10.03B | 13.97B | 14.71B | 17.36B | 33.34B |
| Retained Earnings | -13.76B | -15.17B | -13.53B | -12.97B | -10.53B | -10.95B | -6.96B | -5.96B | -3.80B | 13.61B |
| Total Debt | 1.82B | 1.78B | 1.67B | 2.11B | 1.43B | 3.19B | 2.35B | 2.22B | 32.48B | 35.80B |
| Net Cash (Debt) | 1.74B | 1.52B | 1.55B | 692.00M | 739.00M | -1.01B | -370.00M | -434.00M | -31.51B | -34.81B |
This table shows 10 annual periods of Teva Pharmaceutical Industries's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TEVA's reporting calendar. What is a balance sheet?